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Sirtuin 3, and reduces protein lysine acetylation in diabetic 
cardiac mitochondria. We identified that lysine acetyla-
tion on 83 sites in 34 proteins is lower in the MB-treated 
diabetic group compared to the same sites in the untreated 
diabetic group. These changes occur across critical mito-
chondrial metabolic pathways including fatty acid transport 
and oxidation, amino acid metabolism, tricarboxylic acid 
cycle, ETC, transport, and regulatory proteins. While the 
MB treatment has no effect on the activities of acyl-CoA 
dehydrogenases, it decreases 3-hydroxyacyl-CoA dehy-
drogenase activity and long-chain fatty acid oxidation, and 
improves cardiac function. Providing an alternative route 
for mitochondrial electron transport is a novel therapeutic 
approach to decrease lysine acetylation, alleviate cardiac 
metabolic inflexibility, and improve cardiac function in 
diabetes.
Keywords Cardiomyopathy · Diabetes · Mitochondria · 
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Abstract Diabetic cardiomyopathy is preceded by mito-
chondrial alterations, and progresses to heart failure. We 
studied whether treatment with methylene blue (MB), a 
compound that was reported to serve as an alternate elec-
tron carrier within the mitochondrial electron transport 
chain (ETC), improves mitochondrial metabolism and car-
diac function in type 1 diabetes. MB was administered at 
10  mg/kg/day to control and  diabetic rats. Both echocar-
diography and hemodynamic studies were performed to 
assess cardiac function. Mitochondrial studies comprised 
the measurement of oxidative phosphorylation and spe-
cific activities of fatty acid oxidation enzymes. Proteomic 
studies were employed to compare the level of lysine 
acetylation on cardiac mitochondrial proteins between the 
experimental groups. We found that MB facilitates NADH 
oxidation, increases  NAD+, and the activity of deacetylase 
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ETC  Electron transport chain
NADH  Nicotinamide dinucleotide reduced
NAD+  Nicotinamide dinucleotide oxidized
FA  Fatty acid
Sirt 3  Sirtuin 3
MCAD  Medium-chain acyl-CoA dehydrogenases
LCAD  Long-chain acyl-CoA dehydrogenases
HADH  Hydroxyacyl-coenzyme A dehydrogenase
PC  Palmitoylcarnitine
CTL  Control
CTL+MB  Control+Methylene blue
DB  Diabetic
DB+MB  Diabetic+Methylene blue
Introduction
Diabetic cardiomyopathy evolves from hypertrophy and 
fibrosis with myocardial stiffness to drive cardiac dysfunc-
tion and heart failure in humans [1, 2]. This progression 
has been recapitulated in a number of animal models [3, 
4]. Even in well-controlled diabetic patients, signs of car-
diomyopathy are often present [1, 2, 5]; however, targeted 
therapies do not exist.
The molecular mechanisms regulating diabetic car-
diomyopathy are unknown. Cardiac metabolic inflex-
ibility with excessive reliance on mitochondrial fatty acid 
(FA) oxidation for ATP production is considered a key 
pathogenic mechanism [3]. This metabolic inflexibility is 
due to either insulin lack/insensitivity that decreases glu-
cose uptake and oxidation or metabolic remodeling that 
enhances mitochondrial FA oxidation. Interestingly, over-
reliance on lipids precedes cardiac insulin resistance in 
obese human subjects [6] and rodents [7], and is an early 
event following increased FA availability [8], suggesting 
that the metabolic rigidity of the diabetic heart is linked 
to increased FA availability rather than decreased cardiac 
insulin activity.
Myocardial overreliance on FA oxidation is preceded 
by an increase in circulating FA in diabetes (DB) [9]. 
While cardiac FA uptake increases in DB [10], how mito-
chondrial FA oxidation is up-regulated is unknown. Post-
translational modification by the metabolic end-product, 
acetyl-CoA, can regulate cardiac metabolic enzymes in a 
dynamic, reversible manner. Increased lysine acetylation 
of mitochondrial proteins and insulin signaling machinery 
[11] has been suggested to drive early changes in substrate 
selection. Whereas lysine acetylation depends on acetyl-
CoA, deacetylation is mediated by sirtuins and deacety-
lases are regulated by  NAD+. Lysine acetylation-mediated 
metabolic regulation has been the aim of numerous studies, 
though whether protein lysine acetylation plays a role in 
the etiology of metabolic inflexibility in the diabetic heart 
remains unclear. Individual FA oxidation enzymes are 
sirt3 substrates, and sirt3 knockout leads to their inhibition 
[12]. In contrast, high fat feeding [11] and type 1 diabetes 
[13] lead to hyper-acetylation of FA β-oxidation enzymes, 
and increases cardiac lipid oxidation. Although metabolic 
inflexibility in the diabetic heart is a recognized phenome-
non, how the overreliance on FA oxidation disrupts cardiac 
physiology is unknown. In murine models of type 2 diabe-
tes [14, 15] and obese humans [16] increased mitochondrial 
FA oxidation diminishes cardiac mechanical efficiency [17] 
by FA-induced uncoupling of oxidative phosphorylation 
whereas in models of type 1 diabetes, mitochondrial uncou-
pling is not evident [18].
Substrate oxidation generates reducing equivalents for 
use by the mitochondrial electron transport chain (ETC) 
to drive ATP synthesis. Alternative electron transport 
pathways were reported to rescue mitochondrial dysfunc-
tion induced by ETC deficiencies [19]. Chemical moieties 
capable of electron shuttling include the aromatic com-
pound methylene blue (MB), a FDA-approved drug used 
for almost a century to treat a wide spectrum of ailments 
[20]. Its ability to participate in redox reactions makes it 
an attractive potential therapeutic drug to ameliorate the 
consequences of ETC defects. MB accepts electrons from 
complex I [21, 22], whereas reduced MB  (MBH2) donates 
electrons to downstream ETC subunits, such as cytochrome 
c [19, 23]. In light of MB’s ability to participate in redox 
reactions we hypothesized that treatment with MB would 
decrease the NADH/NAD+ ratio and facilitate lysine dea-
cetylation in the diabetic heart.
Materials and methods
Reagents
Unless otherwise specified, all reagents were of the highest 
purity grade and purchased from Sigma-Aldrich.
Animal models
All animal experiments were conducted in accordance with 
the Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health (NIH Publi-
cation No. 85 − 23, revised 2011), and approved by the Case 
Western Reserve University and Central Michigan Univer-
sity Institutional Animal Care and Use Committees. Adult, 
2-month-old, male Lewis rats were randomly assigned 
to an experimental group: control (CTL), control+MB 
(CTL+MB), DB, or DB+MB. DB was induced by intra-
peritoneal injection of streptozotocin (55 mg/kg body wt); 
DB was confirmed by the onset of hyperglycemia assessed 
in the tail vein blood (~2 weeks after streptozotocin 
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administration). Low doses (0–0.2) of insulin (neutral pro-
tamine hagedorn) was given subcutaneously up to 3× per 
week in order to avoid a severe hypercatabolic state and 
ketosis without preventing hyperglycemia and glucosuria. 
MB was administered in drinking water immediately fol-
lowing streptozotocin injection, and water intake was moni-
tored weekly. MB shows opposite effects at low and high 
doses (hormetic effect) [24]. Low MB concentrations favor 
reduction, whereas at higher concentrations MB may “re-
route” electrons away from the ETC, disrupting the redox 
balance and acting as a pro-oxidant [25]. Our dose selec-
tion was based on the reported dose of 1–10 mg/kg in acute 
intraperitoneal administration that improved memory in 
mice [26–28]. In addition, the oral dose of 10 mg/kg leads 
to an optimal concentration in the heart tissue [29].
DB animals developed polydipsia, thus MB oral dos-
ing was adjusted to standardize treatment based on water 
intake and individual rat weight to deliver 10 mg MB/kg/
day in CTL and DB rats. Over the 11 weeks water intake 
was (ml/day); CTL = 25.1 ± 0.6 to 23.9 ± 2.0, CTL+MB 
21.25 ± 1.5 to 19.2 ± 1.5, DB 129.2 ± 1.7 to 14 to 1.1 ± 2.1, 
and DB+MB 130 ± 2.2 to 134.9 ± 1.5. MB treatment did 
not alter water intake of DB rats.
Cardiac function was assessed by two-dimensional 
guided M-mode, two-dimensional Doppler flow echocardi-
ography, as described [13, 30, 31]. Hemodynamic param-
eters were further evaluated using a Millar pressure trans-
ducer catheter introduced into the LV via the right carotid 
artery [13, 31]. Following 11 weeks, rats were euthanized 
with pentobarbital (100 mg/kg); blood and the left ventricle 
(LV) were sampled for further analysis. Hyperglycemia was 
quantified by measuring blood glucose concentration (glu-
cose dehydrogenase-based strips) and glycated hemoglobin 
(Variant II total GHb program; BioRad).
In a subset of experiments to investigate the role of sir-
tuin 3 (sirt3) in the deacetylating effect of MB, cardiac tis-
sue was harvested from male, 6-month-old, sirt3 knockout 
(KO) mice (Jackson Laboratory) to isolate cardiac mito-
chondria for analysis in respiration studies.
Immunoblotting
Denatured protein samples from LV tissue or cardiac mito-
chondria were separated by SDS–PAGE (4–12% Tricine 
gel, 50  µg/well), electroblotted onto PVDF membranes, 
and probed with primary (dilution 1:3000) and HRP-conju-
gated secondary antibodies (dilution 1:10,000). Membranes 
were developed using Amersham ECL™ substrates. Densi-
tometric analysis was performed with Image J coupled with 
Multi Gauge V3.0 (Fujifilm Life Science) and the Licor 
Odyssey Fc imaging system (Biotech). Antibodies used 
were against acetyllysine, sirtuin 3, and glyceraldehyde 
3-phosphate dehydrogenase (cell signaling), cytochrome 
c (mitosciences), and atrial natriuretic peptide (thermo 
fisher).
Mitochondrial respiratory studies
Cardiac mitochondria were isolated from freshly harvested 
rat LV using a previously published protocol [32]. For 
experiments with sirt3 KO mice, a combined population of 
cardiac mitochondria was isolated from the whole mouse 
heart to maximize yield for subsequent analysis. Protein 
concentration was determined by the Lowry method. Mito-
chondria were investigated for respiratory properties as 
described [13, 33].
NADH and NAD quantitation
Freshly isolated cardiac mitochondria were incubated 
as outlined for oxidative phosphorylation measure-
ments. One milligram of cardiac mitochondrial protein 
was incubated for 5  min in either oxidative buffer alone 
(baseline) or supplemented with the respiratory substrate 
palmitoylcarnitine+malate (PC). Methylene blue was 
added during PC oxidation at the indicated concentra-
tions. NAD and NADH were extracted and quantified using 
a kit according to the manufacturer’s instructions (cell 
technology).
Sirtuin 3 activity
Sirt3 activity of frozen-thawed mitochondria isolated from 
control (untreated) rat hearts was assessed as deacetyla-
tion of a substrate peptide that emits fluorescence with an 
excitation emission of 340–440 nm using a kit according to 
manufacturer’s instructions (Sirt3 activity kit, Abcam).
Mitochondrial fatty acid oxidation enzyme activities
The activities of medium- and long-chain acyl-CoA dehy-
drogenases (MCAD, LCAD) in cardiac mitochondria 
were measured using medium- and long-chain acyl-CoA 
substrates (octanoyl-CoA and palmitoyl-CoA), phena-
zine ethosulfate (intermediate electron acceptor from 
 FADH2), and oxidized cytochrome c (final electron accep-
tor). Mitochondrial matrix was separated by centrifuga-
tion of freeze-thawed, sonicated, and Triton X-100-treated 
(detergent:protein 1:1) cardiac mitochondria. Hydroxyacyl-
CoA dehydrogenase (HADH) was measured as the reverse 
reaction of 3-ketoacyl-CoA conversion to 3-hydroxyacyl-
CoA with NADH as the electron donor. NADH oxidation 
was monitored as the decrease in absorption at 340 nm.
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Affinity purification of lysine‑acetylated peptides 
for proteomic studies
To evaluate the impact of MB treatment on DB-induced 
acetylation, we used a proteomic approach according to a 
previously published protocol [13]. Briefly, 135  µg mito-
chondrial protein from three rats from each group was 
pooled, electrophoresed, and following separation the entire 
lane was subjected to in-gel trypsin digestion [34]. Tryptic 
peptides from DB and DB+MB samples were labeled with 
16O and 18O [35], respectively, then mixed for differential 
isotopic analysis. Lysine-acetylated peptides were enriched 
by immunoprecipitation with anti-Ac-Lys antibody beads 
(ImmuneChem Pharmaceuticals), and analyzed by LC-MS/
MS using an UltiMate 3000 LC system (Dionex Inc., Sun-
nyvale, California) interfaced with a Velos Pro Ion Trap/
Orbitrap Elite hybrid mass spectrometer (Thermo Scien-
tific, Bremen, Germany) [36]. Lysine-acetylated peptides 
were identified by comparing resultant MS/MS spectra 
against the Swiss-Prot database using Mascot database 
search software (version 2.4, Matrix Science, London, 
UK). Carbamidomethylation of cysteine was set as a fixed 
modification, whereas variable modifications included acet-
ylation of ε-amino group of Lys, oxidation of methionine 
to methionine sulfoxide, and 18O labeling of C-terminal 
carboxyl group. The mass tolerance was set at 10 ppm for 
precursor ions and 0.8  Da for product ions. Strict trypsin 
specificity was applied with one missed cleavage allowed. 
The 16O/18O ratio of each peptide was calculated using Pro-
teomics Tools software (available at https://github.com/
shengqh/RCPA.Tools) [37].
Statistical analysis
Data were evaluated for statistical differences among 
groups using student’s 2-tailed t test and a two-way 
ANOVA followed by Bonferroni’s multiple comparison 
test. Data are reported as mean ± SEM with data repre-
senting n = 3–7 per group. Significance was established at 
p < 0.05.
Results
Clinical, biochemical, echocardiographic, 
and hemodynamic characteristics
To best recapitulate the clinical setting of DB, we used a 
model that included management of DB rats with insulin to 
reduce hypercatabolism and avoid ketosis. Body weights of 
diabetic (DB) rats were lower than treatment-matched con-
trols (CTL); however, DB group did not lose weight over 
the experimental period indicating that insulin prevented a 
hypercatabolic state (Table 1). Methylene blue (MB) treat-
ment did not affect body weight in control (CTL+MB) or 
diabetic rats (DB+MB). DB rats exhibited hyperglycemia 
over the 11-week study as evidenced by increased fasting 
and non-fasting blood glucose concentrations FBG and 
NFBG, respectively (Table 1). MB treatment did not signif-
icantly affect NFBG or FBG, though a trend of an increase 
in NFBG was noted in DB+MB. HbA1c was also increased 
in the DB group as compared to treatment-matched control 
(DB versus CTL, ~38 mmol/mol vs. <9 mmol/mol, respec-
tively) confirming the development of diabetes, and was 
not influenced by the MB treatment.
Cardiac function assessed by echocardiography revealed 
that heart rate was decreased in the DB groups as com-
pared to the respective CTL leading to prolonged ejection 
and contraction/relaxation times which were not altered by 
MB treatment. Fractional shortening was not altered across 
the groups despite a modest trend towards a decrease in the 
DB group. LV end-systolic and -diastolic dimensions were 
increased in DB indicating cardiac remodeling. Ventricular 
dimensions in the DB+MB group were not significantly 
different from CTL+MB as measured by echocardiogra-
phy. In contrast, atrial natriuretic peptide (ANP), a marker 
of pathological hypertrophy, was slightly increased in the 
diabetic heart and normalized by the MB treatment (Addi-
tional file: Figure S1). In vivo LV hemodynamic analyses 
showed that end-systolic and -diastolic pressures along 
with load-dependent indices of contractility, +/−dP/dt, 
were diminished in the hearts of DB rats regardless of MB 
treatment (Table 1). However, most if not all hemodynamic 
parameters trended towards improvement in DB+MB 
as compared to the DB group (for all cardiac functional 
parameters measured, see Additional file: Table S1). Addi-
tionally, end-systolic and -diastolic volumes and stroke 
volumes were altered in DB rats, and were significantly 
improved in the DB+MB group consistent with our echo-
cardiographic data. Furthermore, there was a diabetes-
induced decrease in ejection fraction that was significantly 
improved in DB+MB. Together these data indicate that 
chronic MB treatment leads to improved cardiac function 
in this model of diabetic cardiomyopathy.
MB decreases protein lysine acetylation by increasing 
mitochondrial  NAD+ and sirt3 activity
We previously reported an increase in lysine acetylation 
in cardiac mitochondria from DB rats despite unchanged 
expression of sirt3, and identified FA oxidation enzymes 
as major targets of this post-translational modification 
[13]. The present study confirms that finding, and further 
demonstrates that MB treatment decreases protein lysine 
acetylation in cardiac mitochondria (Fig.  1). Lysine 
acetylation is regulated by acetyl-CoA levels whereas 
Mol Cell Biochem 
1 3
deacetylation is regulated by  NAD+-dependent dea-
cetylases (sirtuins). We hypothesized that MB decreases 
lysine acetylation by changing the mitochondrial redox 
balance in favor of  NAD+.  NAD+ and NADH were quan-
titated and the NADH/NAD+ ratio was calculated in 
intact cardiac mitochondria isolated from naïve normal 
rats oxidizing palmitoylcarnitine (PC) as an energetic 
substrate (Fig. 2a, b). Mitochondrial redox status changed 
in favor of NADH upon oxidation of the energetic sub-
strate. However, the addition of MB (6–18  μM) during 
substrate oxidation causes a dose-dependent decrease in 
NADH and the NADH/NAD+ ratio. Changes in the abso-
lute amount of  NAD+ were less responsive than NADH 
with MB addition; nevertheless, 12 μM MB led to a sig-
nificant increase in  [NAD+] confirming that MB shifts 
the mitochondrial redox status. To investigate the effect 
of this redox change on sirt3, its deacetylating activity 
was observed to be significantly increased in energized 
cardiac mitochondria with MB (12 μM) added (Fig. 2c). 
Nicotinamide (NMD), a sirt3 inhibitor, completely 
abolished the impact of MB on sirt3 activity attesting to 
the specificity of this result.
To further investigate the dependency of MB’s deacety-
lating effect on sirt3 activity, cardiac mitochondria isolated 
from sirt3 KO mice were assessed in respiration studies, 
and changes in the redox status and protein acetylation 
were assessed (Fig.  3). Overall, energized mitochondria 
from sirt3 KO mice developed slightly lower NADH/NAD 
ratios (Fig. 3a). The addition of MB to PC-oxidizing mito-
chondria resulted in a dose-dependent decrease of NADH/
NAD+ ratios in both WT and sirt3 KO cardiac mitochon-
dria (Fig. 3a) that was primarily due to a decrease in NADH 
(Figure S2). Lysine acetylation of mitochondrial proteins 
was increased in sirt3 KO cardiac mitochondria compared 
to WT except under conditions where NMD was added to 
inhibit sirt3 (Fig.  3b, c). Furthermore, lysine acetylation 
was much less sensitive to the addition of MB in sirt KO 
cardiac mitochondria compared to WT (Fig. 3c). We show 
that whereas the MB-induced changes in the NADH/NAD 
ratio are largely independent on sirt3, the deacetylating 
Table 1  Summary of clinical, 
biochemical, echocardiographic, 
and hemodynamic 
characteristics of control 
(CTL), control+methylene 
blue (CTL+MB), 11-week 
diabetic (DB), and 11-week 
diabetic+MB (DB+MB) rats
NFBG non-fasting blood glucose, FBG fasting blood glucose, MPI myocardial performance index, dV dias-
tolic volume, sV systolic volume.
*p < 0.05 CTL (N = 7) versus DB (N = 7), and #p < 0.05 DB (N = 7) versus DB+MB (N = 7). Mean ± SEM. 
Full list of measured parameters can be found in Additional file: Table S1
CTL CTL+MB DB DB+MB
Animal data and circulating metabolites
 BWstart (g) 285.0 ± 6.9 282.0 ± 9.9 285.8 ± 4.4 285.8 ± 3.4
 BWend (g) 359.0 ± 15.9 369.0 ± 16.5 273.0 ± 3.8* 265.0 ± 11.5*
 NFBG (mg/dL) 98.6 ± 1.3 97.3 ± 4.5 400.2 ± 14.9* 456.8 ± 23.9*
 FBG (mg/dL) 99.0 ± 0.5 95.3 ± 2.3 310.6 ± 10.8* 320.1 ± 8.9*
 Hb A1C (%) 2.5 ± 0.1 2.5 ± 0.1 5.6 ± 0.1* 5.6 ± 0.2*
Echocardiographic data
 HR (bpm) 363 ± 10 354 ± 7 284 ± 11* 273 ± 14*
 End-diastolic dia. (cm) 0.79 ± 0.02 0.77 ± 0.02 0.84 ± 0.02* 0.81 ± 0.01
 End-systolic dia. (cm) 0.45 ± 0.03 0.45 ± 0.01 0.50 ± 0.03* 0.44 ± 0.01
 Ejection time (msec) 73 ± 2 74 ± 2 105 ± 7* 108 ± 5*
 Fraction shortening 0.44 ± 0.03 0.43 ± 0.01 0.41 ± 0.01 0.45 ± 0.01
 End-diastolic vol. (ml) 0.52 ± 0.03 0.50 ± 0.03 0.64 ± 0.05* 0.57 ± 0.03
 End-systolic vol. (ml) 0.09 ± 0.01 0.08 ± 0.01 0.13 ± 0.02* 0.10 ± 0.01
LV hemodynamics
 End-systolic vol. (μL) 132.8 ± 11.4 133.4 ± 14.7 199.5 ± 28.5* 149.6 ± 11.4#
 End-diastolic vol. (μL) 477.7 ± 6.3 450.8 ± 27.2 579.7 ± 43.3* 486.8 ± 26.1#
 Stroke vol. (µL) 380.1 ± 22.5 367.5 ± 18.3 454.9 ± 36.9* 419.0 ± 17.1
 End-systolic pressure (mmHg) 118.9 ± 4.8 124.1 ± 6.4 98.6 ± 4.5* 109.0 ± 3.3*
 End-diastolic pressure (mmHg) 6.3 ± 0.5 7.6 ± 0.9 9.3 ± 0.9* 8.8 ± 0.2*
 Ejection fraction (%) 75.6 ± 1.6 78.0 ± 0.9 72.9 ± 2.7* 76.3 ± 1.3#
 +dP/dt (mmHg/sec) 6829 ± 638 7580 ± 559 4464 ± 168* 4870 ± 401*
 −dP/dt (mmHg/sec) 10,292 ± 1027 10,551 ± 1346 4734 ± 420* 4773 ± 407*
 Powermax (mWatts/μL2) 5.4 ± 0.8 7.3 ± 1.1 2.85 ± 0.3* 4.2 ± 0.6#
 Tauweiss (msec) 10.1 ± 0.5 9.7 ± 0.4 19.2 ± 1.1* 19.0 ± 1.1*
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effect of MB is dependent on the mitochondrial deacetylase 
sirt3. Taken together, these data support the link between 
the shift in mitochondrial redox status caused by MB, the 
induction of sirt3 activity, and the decrease in lysine acety-
lation of mitochondrial proteins.
MB alters the global profile of mitochondrial protein 
acetylation with FA oxidation enzymes being the major 
targets
To evaluate individual proteins with lysine acetylation sites 
altered by MB treatment in diabetes, a proteomic analy-
sis was performed on cardiac mitochondria from DB and 
DB+MB rats. We identified 1129 peptides representing 
117 proteins present in both DB and DB+MB mitochon-
dria, and detected 83 lysine acetylation sites on 34 proteins 
(Additional file: Table S2 presents the full proteomic sur-
vey). Acetylation of nearly all enzymes involved in mito-
chondrial FA transport and oxidation were affected by 
MB; the extent of lysine acetylation in the DB+MB group 
was lower compared to the same sites in the DB sam-
ples (Table  2). Relative differences in protein expression 
were much smaller than the changes in acetylated peptide 
amounts indicating that the decrease in acetylation is not 
due to altered protein abundance (Table S2). Interestingly, 
six lysine residues of the mitochondrial trifunctional protein 
subunit α, a protein complex which possesses FA oxida-
tion activities, show decreased acetylation in the DB+MB 
group. Alignment of homologs across several other mam-
malian species demonstrates that four lysine residues (K60, 
519, 569, and 728) are highly conserved (Fig. 6b).
MB decreases long‑chain FA β‑oxidation 
without correcting the diabetes‑induced complex 
I‑ and II‑supported mitochondrial oxidative 
phosphorylation
In order to define whether MB alters FA oxidation in the 
DB heart, the specific activities of several enzymes were 
determined in cardiac mitochondria (Fig. 4). The activity of 
medium- and long-chain acyl-CoA dehydrogenase (MCAD 
and LCAD, respectively) increased with DB (Fig.  4a, b, 
respectively). HADH activity was also increased in DB 
mitochondria (Fig.  4c). Additionally, oxidation of PC 
(a long-chain acyl-CoA derivative) increased in the DB 
group (Fig.  4d). MB treatment did not alter MCAD and 
LCAD activities in the DB group, however, it significantly 
decreased HADH activity and PC oxidation (Fig.  4c, d). 
Our data on enzymes involved in mitochondrial FA oxida-
tion suggest a preferential effect of MB on HDH leading to 
a decrease in its activity.
To further test the effect of long-term MB treatment 
on cardiac mitochondrial function in DB rats, mitochon-
drial respiratory studies were performed on freshly iso-
lated cardiac mitochondria. State 3 respiratory rate (ADP-
dependent, 0.2  mM ADP) with glutamate was decreased 
in the DB group and was not significantly altered by MB 
treatment (Fig. 5a). State 4 respiratory rates (ADP-limited) 
were unchanged by DB as were respiratory control (RCR, 
state3/state4) and ADP/O ratios, indicating preserved res-
piratory coupling. Treatment with MB did not alter RCR or 
ADP/O. Depressed glutamate oxidation was insensitive to 
the dissipation of mitochondrial potential with the uncou-
pler dinitrophenol (DNP), excluding the phosphorylation 
system (phosphate transporter, ATP synthase, and adenine 
nucleotide translocator) as the defective component. Oxi-
dative glutamate rates with high ADP (2  mM) were also 
decreased (Fig. 5b), congruent with the low ADP-induced 
state 3 respiration, indicating that the kinetic properties of 
the adenine nucleotide translocator are not responsible for 
the decreased oxidative phosphorylation in DB. These data 
confirm our previous observation that NADH oxidation by 
complex I, rather than NADH formation (upon glutamate 
oxidation) is affected in DB (Fig.  5b). State 3 respiratory 
rates with succinate were also lower in the DB group versus 
CTL, and were not improved by MB treatment (Fig.  5c). 
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Fig. 1  Methylene blue decreases protein lysine acetylation of car-
diac mitochondria in diabetes. a Lysine acetylation modifications of 
protein extracts from isolated cardiac mitochondria. b Densitometric 
analysis was performed on the indicated portion of the membrane, 
and is shown as lysine acetylation reported to cytochrome c as the 
loading control. *p < 0.05 control (CTL, N = 4) versus diabetic (DB, 
N = 4), and #p < 0.05 diabetic (DB, N = 4) versus diabetic + methylene 
blue (DB+MB, N = 4). Mean ± SEM
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(DHQ, complex III electron donor) (Fig.  5d) and the 
cytochrome c electron donor, TMPD–ascorbate (not shown, 
and [13]), were not altered by DB, indicating functionally 
intact complexes III and IV. No differences were noted in 
the purity of mitochondrial fractions as indicated by citrate 
synthase activity (Fig. 5e). Our data confirm the complex I 
and II defects in the DB heart, and show that MB treatment 
does not ameliorate respiratory rate changes. Therefore, the 
observed MB-induced cardioprotection must occur through 
a mechanism not directly related to the intrinsic functional 
capacity of mitochondrial ETC.
Discussion
Diabetic cardiomyopathy involves changes in the metabolic 
phenotype that are thought to precipitate cardiac dysfunc-
tion which eventually leads to heart failure. In the model 
used in this study, we observed key aspects of the human 
pathological condition associated with the development of 
diabetic cardiomyopathy. Heart rate was decreased in DB 
rats, consistent with the diabetic autonomic cardiac neurop-
athy with decreased adrenergic stimulation (50), and was 
not affected by MB. As we administered insulin to prevent 
hypercatabolism, modest systolic and diastolic dysfunction 
was evident in our study. A trend for improvement of all 
cardiac parameters was noted with MB treatment with sig-
nificant improvement in cardiac volumes (systolic and dias-
tolic) indicating improved whole organ function.
The normal heart is a high energy consumer, and gen-
erates ATP predominantly through mitochondrial oxidative 
phosphorylation, primarily through oxidation of FA [38]. 
Despite a heavy dependence on FA, energy substrate flex-
ibility is critical in maintaining ATP levels to sustain heart 
function; overreliance on FA oxidation in the DB heart pro-
motes a pathological metabolic inflexibility. Therapeutic 
strategies to fine-tune metabolism hold promise in treating 
diabetic cardiomyopathy but, pharmacological approaches 
to decrease circulating FA or partially inhibit cardiac FA 
uptake/β-oxidation have failed in clinical trials [39] imply-
ing a greater complexity to the underlying pathology. Reac-
tive molecular species including acetyl-CoA and reducing 
equivalents (NADH) result from increased lipid oxidation, 
and are suggested to contribute to cardiac pathology [40].
Mitochondrial dysfunction, particularly manifested as a 
defect in complex I of the ETC [13], is believed to be a key 
mechanism in diabetic heart disease. However, complex I 



















































Fig. 2  Methylene blue decreases NADH/NAD ratio and increases 
sirt3 activity in cardiac mitochondria. NADH and  NAD+ amounts (a) 
and NADH/NAD+ ratio (b) in isolated naïve cardiac mitochondria 
oxidizing 0.04 mM palmitoylcarnitine (PC)+malate for 5 min. Meth-
ylene blue (MB) was added at the indicated concentrations (6, 12, and 
18  μM). c Sirtuin 3 activity measured in cardiac mitochondria oxi-
dizing 0.04 mM PC+malate. MB was added at 12 μM concentration. 
Nicotinamide (NMD) was added at 1 mM concentration. Data are the 
results of 3–5 independent experiments. *p < 0.05. Mean ± SEM
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dysfunction under resting, non-stressing conditions [41]. 
In contrast, the complex I defect in DB is not a limiting 
factor in the observed increase in FA oxidation in the dia-
betic heart and does lead to cardiac disease [13], indicating 
that the underlying molecular mechanism of DB cardio-
myopathy extends beyond a decrease in ETC function and 
energy deficit. We previously demonstrated that the com-
plex I defect in diabetes is associated with enhanced protein 
lysine acetylation [42]. While MB acts as an alternative 
electron carrier in complex I defective mitochondria and 
cells by bypassing complex I and provides neuroprotection 
in a murine model of complex I defect [19], evidence that 
it provides a similar electron route and rescues the complex 
I defect in the diabetic heart mitochondria [42] is missing. 
When isolated from the MB-treated diabetic hearts, cardiac 
mitochondria did not exhibit an improvement in complex 
I-dependent oxidative phosphorylation suggesting that the 
type of diabetic-induced complex I defect cannot be cor-
rected by MB. In contrast, we observed the MB’s deacety-
lating effect in cardiac mitochondria after isolation, and 
reproduced it in in vitro experiments. These data indicate 
that lysine acetylation is a stable change, and that MB 
exerts a deacetylating effect disregarding the type of com-
plex I defect.
Complex I not only participates in electron transfer for 
oxidative phosphorylation, but controls mitochondrial 
redox status by oxidizing NADH [41]. Indeed, mitochon-
dria in the resting state favor  NAD+, but when oxidizing an 
energetic substrate such as the long-chain FA derivative PC, 
NADH is relatively high compared to ETC flux and ATP 
synthesis. This redox shift towards NADH diminishes in 
the presence of an alternative electron carrier for complex 
I, MB, leading to increased  [NAD+]. As  NAD+ is the sub-
strate and a potent activator of sirt3, the NADH to  NAD+ 
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Baseline         PC         PC+MB         NMD
Fig. 3  The lysine deacetylating effect of methylene blue is partially 
mediated by sirt3. a NADH/NAD+ ratio in cardiac mitochondria iso-
lated from  sirt3−/− (sirt3 KO) and  sirt3+/+ (wild-type, WT) mice. b 
Lysine acetylation modifications of cardiac mitochondrial proteins in 
 sirt3−/− (sirt3 KO) and  sirt3+/+ (wild-type, WT) mice. c Densitomet-
ric analysis was performed on the indicated portion of the membrane, 
and is shown as lysine acetylation reported to cytochrome c as the 
loading control. Freshly isolated intact mitochondria (0.5  mg Mito) 
were incubated in either respiratory buffer alone (Baseline) or sup-
plemented with palmitoylcarnitine (PC, 0.04 mM) + malate, PC+MB 
(12  μM), and PC+NMD (1  mM). At 5  min, mitochondrial proteins 
were extracted with lysis buffer, separated by PAGE (10  μg/lane) 
and probed with lysine acetylation, sirt3, and cytochrome c antibody. 
Data are the results of 1–3 independent experiments, N = 3 for either 
 sirt3−/− (sirt3 KO) and  sirt3+/+ (wild-type, WT) mice. *p < 0.05. 
Mean ± SEM
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Table 2  Cardiac mitochondrial 
proteins that are hypoacetylated 
at lysine residues in 
diabetic+methylene blue 
(DB+MB) versus diabetic (DB) 
group








 ATP synthase subunit beta (ATP5b) P10719
  K.VLDSGAPIKIPVGPETLGR.I 133 0.35
 ATP synthase subunit b (AT5f1) P19511
  K.AQQALVQKR.H 162 0.38
  R.EKAQQALVQK.R 154 0.28








 ATP synthase subunit O (ATPo) Q06647
  K.RLDQVEKELLR.V 60 0.33
  R.LDQVEKELLR.V 60 0.35




 ADP–ATP translocase 2 (ANT2) Q09073
  R.YFPTQALNFAFKDK.Y 92 0.79
 Cytochrome b-c1 complex subunit 1 QCR2c1 Q68FY0
  K.ALSKDLPK.V 38 1.51





 Cytochrome c oxidase subunit 4 isoform 1 (COX41) P10888
  K.LLSASQKALK.E 60 0.25
Glucose oxidation








nent of 2-oxoglutarate dehydrogenase complex (ODO2)
Q01205
  R.DAFIKKN KDAFLKKH 273 0.23
  R.HKDAFLK.K 268 0.30
  R.HKDAFLKK.H 268, 273 0.05
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 2,4-dienoyl-CoA reductase (DECR) Q64591
  K.QLIKAQK.G 185 0.20




 Acyl-coenzyme A thioesterase 1 (ACOT1) O88267
  R.DEKGALFR.A 42 0.20
  K.VPASKAFTGFIVEADTPGIHIGK.K 217 0.87
 Acyl-coenzyme A thioesterase 2 (ACOT2) O55171
  R.DEKGALFR.A 83 0.20
  R.DVQKPYVVELEVLDGHEPDGGQR.L 141 0.34
 Carnitine O-acetyltransferase (CRAT) Q704S8
  R.VPGLKQDSVVNFLK.S 186 0.12
 Enoyl-CoA delta isomerase 1 (ECI1) P23965
  K.LENDKSIR.G 76 0.23
 Hydroxyacyl-coenzyme A dehydrogenase (HADH) Q9WVK7
  K.TLSSLSTSTDAASVVHSTDLVVEAIVENLKLK.N 125 0.91
 Long-chain specific acyl-CoA dehydrogenase (LCAD) P15650
  K.AFGKTVAHIQTVQHK.L 322 0.33
 Medium-chain specific acyl-CoA dehydrogenase (MCAD) P08503
  K.VPASKAFTGFIVEADTPGIHIGK.K 217 0.87
 Short-chain specific acyl-CoA dehydrogenase (SCAD) P15651
  R.HAFGAPLTKLQNIQFK.L 306 0.31







 Trifunctional enzyme subunit beta (HADHb) Q60587
  R.TNIPKDVVDYIIFGTVIQEVK.T 96 0.04
TCA cycle













 Isocitrate dehydrogenase [NADP] (IDH2) P56574
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shift with MB should directly increase sirt3 deacetylation 
activity. Indeed, our data from substrate-oxidizing mito-
chondria demonstrate increased sirt3 activity with the addi-
tion of MB. Sirtuin 3 (sirt3), the master regulator of mito-
chondrial deacetylation, has been classically recognized 
as a  NAD+-reliant deacetylase and negative regulator of 
cardiac hypertrophy [43, 44]. Recent studies using in vitro 
approaches have suggested that NADH also inhibits sirt3 
at concentrations that are non-physiologic [41, 45]. This 
has led to the notion that NADH does not likely regulate 
sirt3 activity in vivo [45]. However, early work on sirtuins 
hinted at a role for inhibition by [NADH] in yeast where 
 NAD+/NADH ratios changed without altered  NAD+; this 
was accompanied by sirtuin activation (with supporting 
in vitro data in the micromolar range) [46]. More recently, 
intact mitochondria from mice bearing a genetic defect in 
complex I, the major NADH oxidation site, do not alter 
 NAD+ concentrations but rather show a significant increase 
in NADH compared to WT mice and a dramatic increase 
in lysine acetylation of mitochondrial proteins. Based on 
these in vivo findings and our previous work showing that 
decreased NADH consumption at complex I leads to ele-
vated mitochondrial lysine acetylation in the DB heart [42], 
we assert that NADH also affects sirt3 activity. Our present 
data concurs as NADH was more responsive than  NAD+ 
to MB at µM concentrations in respiring mitochondria 
(Fig. 2a).  NAD+ also modestly but significantly increased 
at higher MB concentrations. MB also increased sirt3 
activity (Fig. 2c). The link between NADH and sirt3 activ-
ity is further evidenced in mitochondria from WT and sirt3 
KO mice where an MB-dependent decrease in the NADH/
NAD+ ratio (Fig. 3a) was due to decreased NADH (Supple-
mentary Fig. 2) and was accompanied by a suppression of 
acetylation only in WT; the absence of sirt3 abolished this 
effect (Fig. 3b, c). Though other factors that influence sir-
tuin activity warrant further investigation, our data firmly 




















 ES1 protein homolog P56571
  K.GVTEAHVDQKNK.V 131 0.33
 NEDD8-conjugating enzyme (UBE2f) Q5U203
  R.VSVRDKLLVK.E 35, 39 0.29
 Phenylalanine–tRNA ligase alpha subunit (FARSa) Q505J8
  R.VDKSAADGPR.V 117 0.88
 Stress-70 protein (HSPa9a) P48721
  R.AQFEGIVTDLIKR.T 348 0.64
  R.HIVKEFK.R 288 0.20
Bold and underlined acetylated lysine residue in analyzed peptide fragment
Lysine position given refers to full protein sequence
Acetylation ratio reported as DB−MB:DB
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implicate a role for increased sirt3 activity as part of mech-
anism underlying MB-induced cardioprotection of the DB 
heart.
The data presented here with cardiac mitochondria 
from sirt3 KO mice demonstrate that mitochondrial redox 
state during substrate oxidation is modestly affected by the 
absence of sirt3, as previously reported [43]. Mitochondrial 
protein acetylation is increased in the absence of sirt3 and 
less sensitive to MB addition when compared to the WT 
mice. This effect is not evenly distributed as only the lysine 
acetylation of some proteins is sensitive to the addition 
of MB, an observation also confirmed by our proteomic 
approach. Our data imply that sirt3 activation is central to 
the lysine deacetylating effect of MB on some specific pro-
teins, further linking mitochondrial redox status to the acti-
vation of sirt3. The absence of sirt3 does not fully abolish 
the effect of MB on acetylation suggesting that, although 
critical to mitochondrial protein deacetylation, sirt3 is not 
the sole deacetylase at least for some specific proteins. 
For example, lysine acetylation of the α subunit of trifunc-
tional protein induced by sirt4, also a mitochondrial dea-
cetylase, increases the protein stability by inhibiting ubiq-
uitination, and promotes FA oxidation [47]. In contrast to 
this finding, sirt4 deacetylates and inhibits malonyl-CoA 
decarboxylase, an enzyme that converts malonyl-CoA, an 
inhibitor of mitochondrial FA oxidation, to acetyl-CoA, the 
carbon skeleton for lipogenesis; in this setting sirt4 limits 
mitochondrial FA oxidation [48]. These data emphasize 
the versatility of mitochondrial sirtuins to regulate FA 
metabolism. Also, MB-induced changes may be related to 
sirt3-mediated increases in antioxidant defense [44] which 
deserves further investigation. In systemic administration, 
MB is reported to be an inhibitor of guanylate cyclase 
[49] and reverses the nitric oxide-induced hypotension and 
vasoplegic syndrome [50], and acts as a redox compound 
in other tissues. As MB reportedly inhibits monoamine 
oxidase A [51], a source of oxidative stress in the diabetic 
























































CTL CTL+MB DB DB+MB CTL CTL+MB DB DB+MB 
Fig. 4  Methylene blue decreases mitochondrial fatty acid β-oxidation 
in diabetes. Specific activities of mitochondrial fatty acid β-oxidation 
enzymes were assessed spectrophotometrically in the presence of 
electron donors and acceptors in cardiac mitochondria. Medium-
chain (a) and long-chain (b) acyl-CoA dehydrogenases (MCAD and 
LCAD) use the oxidation of specific substrates (octanoyl-CoA and 
palmitoyl-CoA) to reduce cytochrome c with phenazine ethosul-
fate as the intermediate electron acceptor from FADH2 bound to the 
enzyme. c Long-chain hydroxyacyl-CoA dehydrogenase (α-chain of 
the mitochondrial trifunctional protein) was measured as the back-
ward conversion of acetoacetyl-CoA to hydroxyacetyl-CoA and 
NADH oxidation. d Mitochondrial fatty acid β-oxidation was meas-
ured as the maximal oxidation of PC+malate by intact cardiac mito-
chondria in the presence of 2  mM ADP. *p < 0.05 control (CTL, 
N = 4–7) versus diabetic (DB, N = 4–7), and #p < 0.05 DB (N = 4–7) 
versus diabetic+MB (DB+MB, N = 4–7). Mean ± SEM
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role may have also contributed to the improvement of car-
diac function. Regardless, in our whole animal studies in 
a diabetic rat model, the increase in protein acetylation 
observed in DB was diminished by treatment with MB and 
cardiac function was improved; this underscores the physi-
ological relevance of the biochemical effect of mitochon-
drial redox state on protein acetylation in the heart.
The functional consequences of lysine acetylation in 
the context of our biochemical data and the impact on FA 
oxidation is of interest in defining how DB and MB affect 
cardiac metabolism. First, we assessed mitochondrial 
FA oxidation through specific activities of several reac-
tions involved in FA oxidation. As indicated by PC oxida-
tion, overall FA oxidation was enhanced in DB hearts and 
MB treatment decreased oxidation, which is consistent 
with our hypothesis that MB should reduce FA metabo-
lism, along with protein acetylation. The activities of 
MCAD and LCAD, enzymes catalyzing the initial steps 
of FA metabolism, were increased by DB consistent with 
increased FA oxidation. However, MB treatment did not 
affect MCAD and LCAD activities despite an anticipated 
decrease to accompany our observation of reduced protein 
acetylation. The activity of HADH, an enzyme catalyzing 
a downstream step of FA oxidation was also increased in 
the hearts of DB rats. In contrast to MCAD and LCAD, its 
activity was decreased with MB treatment. Together, the 
data suggest specific targeting of mitochondrial FA path-
way proteins by MB-induced lysine deacetylation.
To gain more insight on MB-induced changes in lysine 
acetylation of mitochondrial proteins, a non-targeted 
approach was employed to generate a proteomic pro-
file. MB decreases protein acetylation in a broad range of 
mitochondrial metabolic pathways including FA transport 
and oxidation, amino acid metabolism, tricarboxylic acid 
cycle, ETC, mitochondrial membrane transport, and regu-

















































CTL CTL+MB DB DB+MB 
Citrate Synthase
A
279.4 ± 14.9 241.8 ± 5.4 160.0 ± 10.8 186.8 ± 20.6
17.7 ± 1.6 20.3 ± 5.6 14.0 ± 2.8 14.7 ± 2.1
16.3 ± 1.6 13.1 ± 3.4 13.0 ± 2.8 13.8 ± 3.6
2.88 ± 0.06 2.88 ± 0.16 2.93 ± 0.08 2.82 ± 0.11
280.5 ± 14.5 281.2 ± 13.9 171.7 ± 16.9 196.7 ± 23.8









Fig. 5  Methylene blue does not correct the diabetes-induced 
decrease in complex I- and II-supported oxidative phosphorylation in 
cardiac mitochondria. a Glutamate was used as substrate. State 3 res-
piratory rate (ADP-dependent) was induced by 0.2  mM ADP. State 
4 respiratory rate (ADP-limited) was recorded after ADP consump-
tion. RCR-Respiratory Control Ratio (State 3/State 4). ADP/O is the 
number of ADP molecules added for each oxygen atom consumed. 
Respiratory rates are expressed as nAO/min/mg mitochondrial pro-
tein. Maximal (2 mM) ADP-stimulated respiratory rates were meas-
ured with substrates that donate the reducing equivalents to com-
plexes I (glutamate, b), II (Succinate+Rotenone, c), and III (DQ+R, 
Duroquinol+Rotenone, d). e Specific activity of citrate synthase. 
*p < 0.05. CTL = Control (N = 7), CTL+MB = Control+methylene 
blue (N = 7), DB = Diabetic (N = 7), DB+MB = Diabetic + methylene 
blue (N = 7). Mean ± SEM
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evenly distributed (fold changes between 0.06 and 0.91). 
Processes related to FA-derived acetyl-CoA were heav-
ily affected as numerous FA β-oxidation pathway enzymes 
had at least one lysine target. This included acetylation 
of three lysine residues in the short-, medium-, and long-
chain acyl-CoA dehydrogenases that decreased with MB 
treatment. Although substrate length specificity varies, 
the catalytic mechanism of MCAD and LCAD is similar; 
all enzymes transfer protons from acyl-CoA to FAD with 
the reducing equivalents being transferred to the electron 
transfer flavoprotein with final disposition into the ETC via 
coenzyme Q. The activities of these enzymes in DB hearts 
were increased; however, MB did not alter acyl-CoA dehy-
drogenase activities despite decreasing lysine acetylation. It 
was previously reported that LCAD lysine residues 318 and 
322 are sirt3 targets, and dual acetylation decreases activity 
[12]. We suggest that there may exist a synergistic effect of 
acetylating both lysine residues not present in our model, as 
increased acetylation occurred solely on lysine 322 in the 
DB group associated with increased enzyme activity.
A major target of decreased acetylation with MB treat-
ment was the mitochondrial trifunctional protein complex 
(Fig. 6b), a large hetero-multimeric enzyme catalyzing the 
three final steps of long-chain FA β-oxidation. It comprised 
four α-subunits with long-chain enoyl-CoA hydratase and 
3-hydroxyacyl-CoA dehydrogenase (HADH) activities, and 
four β-subunits harboring the long-chain 3-ketoacyl-CoA 
thiolase activity. The α subunit is reported to be heavily 
SP|Q64428|RAT 50  VIRINSPNSK 60
SP|Q8BMS1|MOUSE 50  VIRINSPNSK 60
SP|P40939|HUMAN 50  VVRINSPNSK 60
SP|Q29554|PIG 50  VIRINSPNSK 60
SP|Q64428|RAT 436 KGFEKADMVI 445 
SP|Q8BMS1|MOUSE 436 KGFEKADMVI 445 
SP|P40939|HUMAN 436 QGFEKADMVI 445 
SP|Q29554|PIG 436 QGFEKADMVI 445
SP|Q64428|RAT 519 KDTTASAVAVGLK 531
SP|Q8BMS1|MOUSE 519 KDTTASAVAVGLR 531
SP|P40939|HUMAN 519 KDTSASAVAVGLK 531
SP|Q29554|PIG 519 KDSTASAVEVGLK 531
SP|Q64428|RAT 560 ILQEGVDPKKLDA 573
SP|Q8BMS1|MOUSE 560 ILQEGVDPKKLDA 573
SP|P40939|HUMAN 560 ILQEGVDPKKLDS 573
SP|Q29554|PIG 560 ILQEGVGPKKLDS 573
SP|Q64428|RAT 728 KVVDRLRKYE 737
SP|Q8BMS1|MOUSE 728 KVVDRLRKYE 737
SP|P40939|HUMAN 728 KIVDRLKKYE 737





































Fig. 6  Methylene blue decreases mitochondrial lysine acetyla-
tion and relieves the metabolic inflexibility of the diabetic heart by 
facilitating NADH oxidation. a Target classification of MB-mediated 
decreases of protein lysine acetylation in diabetes. MB decreases 
lysine acetylation of proteins across several mitochondrial metabolic 
pathways including fatty acid transport and oxidation (FAO), tri-
carboxylic acid cycle (TCA), electron transport chain (ETC), mito-
chondrial membrane transport and regulatory proteins, and amino 
acid metabolism. b Multiple sequence alignment of the mitochon-
drial trifunctional protein α subunit. The mouse, human, and pig 
proteins were aligned with the rat protein. The alignment was cre-
ated with CLUSTAL program available at http://www.uniprot.org/
align. Domain was built based on information found at http://www.
ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi. c Proposed lysine dea-
cetylating effect of MB in the diabetic heart. The diabetes-induced 
mitochondrial complex I defect limits the oxidation of NADH. MB 
facilitates NADH oxidation, thus increasing  NAD+ and the activity of 
the  NAD+-dependent deacetylase sirt3, and decreasing lysine acetyla-
tion of FA oxidation enzymes and metabolic inflexibility. FMN Flavin 
mononucleotide; Fe–S + Iron sulfur centers;  C I, III, and IV  Com-
plexes I, III, and IV; Cyr c Cytochrome c; MOM Mitochondrial outer 
membrane; IMS Intermembrane space; MIM Mitochondria inner 
membrane
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lysine acetylated normally [52] and in diabetes [13]. We 
found six lysines that exhibit decreased acetylation with 
MB treatment in DB suggesting finely tuned regulation 
through multiple acetylation sites; four of these lysines 
were identified by Rardin et al. as sirt3 targets [52]. How-
ever, lysines 531 and 569, located within the 3-hydroxya-
cyl-CoA dehydrogenase, are novel to this study. Lysines 60, 
519, 569, and 728 are conserved among mammalian spe-
cies, supporting a role in regulating function, though the 
functional consequences are a matter of debate. Hyper-acet-
ylation inhibits the enzyme in mice lacking cyclophilin D 
[53], whereas it activates the enzyme in mice with high fat 
diet (HFD)-induced obesity [11]. The sites of acetylation 
have not been provided by these studies. Our study suggests 
that with increased FA availability, enhanced acetylation at 
lysines 531 and 569 is associated with enzyme activation 
in the DB heart. Our results also indicate that decreased 
lysine acetylation of FA oxidation enzymes with MB treat-
ment positively correlates with a decrease in the overall FA 
β-oxidation pathway, suggesting a protective effect of this 
compound on the excessive reliance of the heart on FA oxi-
dation in diabetes. Future studies will need to validate and 
elucidate how site-specific lysine acetylation modulates the 
enzyme function.
Currently there is no consensus regarding the effect of 
lysine acetylation on mitochondrial FA oxidation in the 
diabetic heart. Using approaches that overexpress or knock-
down sirt3, FA oxidation enzymes are reported to be dea-
cetylated and activated by sirt3 in the liver [12, 54]. How-
ever, cultured HEK293 cells exposed to histone deacetylase 
inhibitors exhibit an increased lysine acetylation and acti-
vation of enoyl-coenzyme A hydratase/3-hydroxyacyl-
coenzyme A dehydrogenase in mitochondrial FA oxidation 
[55]. In addition, in a rodent model of T1D we found an 
increased lysine acetylation of FA oxidation enzymes in the 
heart in the presence of unchanged sirt3 amount and associ-
ated with increased mitochondrial FA oxidation supported 
by an increased activity of FA oxidation enzymes [42]. 
Similarly, HFD regimen led to increased lysine acetylation 
of FA oxidation enzymes and mitochondrial FA oxidation 
in the heart [11]. Therefore, mitochondrial FA oxidation 
enzymes are hyperacetylated and activated in the context 
of increased FA availability to the heart regardless of sirt3 
amount suggesting that additional levels of regulation may 
operate during these conditions. Mechanisms that control 
this context-specific response have just begun to be investi-
gated. One operative mechanism is provided by heat shock 
protein 10 (a sirt3 substrate) that, when acetylated, induces 
an optimal folding of the FA oxidation protein enzymes 
enhancing their activity and overall mitochondrial FA oxi-
dation during HFD [56], a condition that is also associated 
with a decrease in the  NAD+/NADH redox ratio and sirt3 
activity.
In addition, the role of increased acetyl-CoA derived 
from the oxidation of excessive fuel substrates in diabetes 
(glucose, FA) has begun to be appreciated. The impor-
tance of acetyl-CoA is supported by experiments in mice 
bearing a deficiency of carnitine acetyltransferase that 
transports the excessive acetyl-CoA from mitochondria 
to cytosol; these mice exhibit increased mitochondrial 
lysine acetylation induced by excessive mitochondrial 
acetyl-CoA [57]. Acetyl-CoA is the substrate and acetyl 
group donor for acetyltransferases to acetylate lysine 
groups on proteins. The mitochondrial acetyltransferase, 
GCN5-1, counteracts the sirt3 deacetylating effect on 
mitochondrial proteins [58]. With low binding affinity for 
acetyl-CoA, all acetyltransferases are reliant on acetyl-
CoA availability [59] and may be inhibited by CoA sug-
gesting that the acetyl-CoA/CoA is equally important for 
lysine acetylation [60]. In addition, excessive acetyl-CoA 
can promote non-enzymatic lysine acetylation [61, 62]. 
Compounds resulting from oxidation of the large avail-
ability of fuel substrates, including acylcarnitines and 
acetyl-CoA, accumulates upon HFD [63]. Therefore, 
non-enzymatic lysine acetylation is operative during an 
excess energetic supply to the heart leading to acetyla-
tion of lysine sites other than those reported to be sirt3 
targets. We propose that in the diabetic heart the non-
enzymatic (and most likely non-specific) lysine acetyla-
tion activates mitochondrial FA oxidation and overrides 
the inhibitory effect of lysine acetylation at mitochondrial 
sirt3 lysine targets.
Collectively, our data support the concept that mito-
chondrial ETC dysfunction is an important arbitrator of 
diabetic cardiomyopathy, and leads to a shift in mito-
chondrial redox status that favors lysine acetylation of 
FA oxidation enzymes and contributes to the exces-
sive reliance of FA oxidation in the diabetic heart. This 
work also highlights a novel therapeutic approach in 
diabetes; the use of mitochondrial alternative electron 
carriers to decrease lysine acetylation, and alleviate the 
metabolic rigidity and cardiac dysfunction of the dia-
betic heart. Figure  6c shows a proposed mechanism for 
the lysine deacetylating effect of MB. In the mitochon-
drial ETC, electrons are passed from NADH via several 
donors and acceptors to oxygen in order to form water. 
The energy obtained through this electron transfer is 
used by complexes I, III, and IV to pump protons into the 
intermembrane space creating an electrochemical gra-
dient that is further used by ATP synthase to phospho-
rylate ADP to ATP. Diabetic-induced complex I defect 
causes a decrease in NADH oxidation. In the experimen-
tal models of rotenone-induced complex I defect MB 
accepts electrons from catalytic subunits of complex I 
and become reduced (MBH2) whereas cytochrome c 
reoxidizes MBH2 to MB [20]. Therefore, MB provides 
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an alternative electron route within the diabetic complex 
I-deficient cardiac mitochondria and favors NADH oxida-
tion, increased  NAD+, and sirt3 activity.
MB was reported to accumulate with high affinity in 
tissues including liver and heart, increase the cellular 
 NAD+/NADH ratio, and enhance sirt1 expression in the 
liver [29]. Our study adds to these findings and show that 
MB also accumulates within mitochondria, and estab-
lishes the causal link between the MB-induced decrease 
in the NADH/NAD+ ratio and activation of mitochon-
drial sirt3 with limitation of the specific activity of the 
hydroxyacyl-CoA dehydrogenase and FA β-oxidation, 
and functional improvement of the diabetic heart. We 
propose that MB-mediated protein deacetylation of FA 
metabolism enzymes is directly linked to improved car-
diac function in DB. Whether this is the sole mechanism 
of cardioprotection by MB requires further investigation. 
Future work on site-directed mutagenesis of MB tar-
geted-lysine residues will aid in establishing the relation-
ship between this post-translational modification and the 
change in the enzyme-specific activity.
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